157: Clinical Advances and Unanswered Questions in Narcolepsy
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
-
Narrado por:
-
De:
In this episode, "Clinical Advances and Unanswered Questions in Narcolepsy," Lindsay McCullough, MD, discusses how clinical understanding of narcolepsy has evolved, where major diagnostic and treatment advances have occurred, and where important gaps remain. McCullough, assistant professor of medicine and associate program director for the sleep medicine fellowship at Rush University, reflects on progress in defining narcolepsy subtypes, the growing role of orexin biology, and how recent research in 2025 has reshaped conversations around disease-modifying approaches. The discussion also explores emerging links between sleep disorders and neurodegenerative disease, common misconceptions that continue to delay diagnosis, and how clinician education can improve recognition, safety, and long-term management of patients with narcolepsy.
Looking for more Sleep Disorder discussion? Check out the NeurologyLive® Sleep Disorder clinical focus page.
Episode Breakdown:
- 1:05 – Advances and remaining gaps in the clinical understanding of narcolepsy
- 2:30 – How narcolepsy care and research meaningfully evolved throughout 2025
- 4:50 – Sleep disorders, neurodegeneration, and what clinicians should watch for
- 6:50 – Neurology News Minute
- 8:50 – Persistent myths that delay diagnosis and affect clinical decision-making
- 12:30 – How lived experience shapes holistic, patient-centered narcolepsy care
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis
- FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS
- Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
Todavía no hay opiniones